Back
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
Journal article

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

  • Villard, Linda Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Romer, Anna Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Marincek, Nicolas Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Brunner, Philippe Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Koller, Michael T. Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Schindler, Christian Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Ng, Quinn K.T. Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Mäcke, Helmut R. Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Müller-Brand, Jan Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Rochlitz, Christoph Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Briel, Matthias Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
  • Walter, Martin A. Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael T. Koller, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller-Brand, Christoph Rochlitz, Matthias Briel, and Martin A. Walter, University Hospital Basel; Christian Schindler, University of Basel, Basel, Switzerland; Matthias Briel, McMaster University, Hamilton, Ontario, Canada; and Martin A. Walter, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA.
Show more…
Published in:
  • Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2012, vol. 30, no. 10, p. 1100-1106
Cancer Research
Oncology
English Purpose Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes. Patients and Methods In a cohort study, patients with metastasized neuroendocrine cancer were treated with repeated cycles of 90yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([90Y-DOTA]-TOC) or with cycles alternating between [90Y-DOTA]-TOC and 177lutetium-labeled DOTA-TOC ([177Lu-DOTA]-TOC) until tumor progression or permanent toxicity. Multivariable Cox regression and competing risk regression were used to study predictors of survival and renal toxicity in patients completing three or more treatment cycles. Results A total of 486 patients completed three or more treatment cycles; 237 patients received [90Y-DOTA]-TOC and 249 patients received [90Y-DOTA]-TOC + [177Lu-DOTA]-TOC. Patients receiving [90Y-DOTA]-TOC + [177Lu-DOTA]-TOC had a significantly longer survival than patients receiving [90Y-DOTA]-TOC alone (5.51 v 3.96 years; hazard ratio, 0.64; 95% CI, 0.47 to 0.88; P = .006). The rates of severe hematologic toxicities (6.3% v 4.4%; P = .25) and severe renal toxicity (8.9% v 11.2%; P = .47) were comparable in both groups. Conclusion [90Y-DOTA]-TOC + [177Lu-DOTA]-TOC was associated with improved overall survival compared with [90Y-DOTA]-TOC alone in patients completing three or more cycles of treatment. Contrary to the current practice in radiopeptide therapy, our results suggest an advantage of using a combination of radioisotopes.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/195049
Statistics
Document views: 19 File downloads: